Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA planning new update for ESA labels

AMGN fell $3.05 to $52.10 on Friday after announcing late Thursday that it is in discussions with FDA about planned updates to the safety information on the labels of all erythropoiesis-stimulating agents

Read the full 322 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers